Clarus Wealth Advisors purchased a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,052 shares of the biopharmaceutical company’s stock, valued at approximately $560,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. Vanguard Group Inc. lifted its holdings in Bristol-Myers Squibb by 1.2% during the second quarter. Vanguard Group Inc. now owns 134,058,636 shares of the biopharmaceutical company’s stock valued at $6,079,559,000 after purchasing an additional 1,580,750 shares in the last quarter. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 6.7% during the second quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after purchasing an additional 7,178,698 shares in the last quarter. FMR LLC lifted its holdings in Bristol-Myers Squibb by 313.9% during the first quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock valued at $1,949,043,000 after purchasing an additional 30,981,844 shares in the last quarter. Invesco Ltd. lifted its holdings in Bristol-Myers Squibb by 40.4% during the second quarter. Invesco Ltd. now owns 24,012,686 shares of the biopharmaceutical company’s stock valued at $1,088,974,000 after purchasing an additional 6,915,526 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Bristol-Myers Squibb by 67.6% during the second quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock valued at $938,682,000 after purchasing an additional 8,347,432 shares in the last quarter. 80.17% of the stock is currently owned by hedge funds and other institutional investors.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini bought 11,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, July 31st. The stock was acquired at an average cost of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the transaction, the director now directly owns 11,397 shares of the company’s stock, valued at $509,673.84. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.
Shares of NYSE BMY traded up $1.07 during mid-day trading on Friday, reaching $51.85. The company’s stock had a trading volume of 906,020 shares, compared to its average volume of 9,791,409. The stock has a 50-day moving average of $49.24 and a two-hundred day moving average of $47.03. The stock has a market capitalization of $82.38 billion, a P/E ratio of 12.97, a P/E/G ratio of 2.48 and a beta of 0.72. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $60.77.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 earnings per share. Analysts predict that Bristol-Myers Squibb Co will post 4.29 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Rule of 72
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.